Citations

Showing 10 of 108104 citations.

NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022
Gillison, Maura L. , Maghami, Ellie, Spencer, Sharon, Pfister, David G. , Birkeland, Andrew C. , Busse, Paul M., Cmelak, Anthony J. , Eisele, David W. , Galloway, Thomas J. , Geiger, J.L. , Haddad, Robert I. , Hicks, Wesley L. , Hitchcock, Ying J. , Jimeno, Antonio , Leizman, Debra S., Mell, Loren K. , Mittal, Bharat B. , Pinto, Harlan A. , Rocco, James W. , Rodriguez, Cristina P. , Savvides, P. , Sher, David J. , Weber, Randal S. , Weinstein, Gregory S., Worden, Frank , Yom, Sue S. , Zhen, Weining, Burns, Jennifer L. , Darlow, Susan, Savvides, Panayiotis S, Haddad, Robert , Mittal, Bharat B , Yom, Sue S , Caudell, Jimmy J , Adkins, Douglas R. , Brizel, David M. , Colevas, Alexander Dimitrios , Schwartz, David A. , Shah, Jatin P. , John, Maie A. St. , Bruce, Justine Y.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 11, 2022 | Volume: 20 | Issue: 3 | Pages: 224-234

10.6004/jnccn.2022.0016 | PMID 35276673 Get It

The NCCN Guidelines for Head and Neck Cancers address tumors arising in the oral cavity (including mucosal lip), pharynx, larynx, and paranasal sinuses. Occult primary cancer, salivary gland cancer, and mucosal melanoma (MM) are also addressed. The specific site of disease, stage, and pathologic findings guide treatment (eg, the appropriate surgical procedure, radiation targets, dose and fractionation of radiation, indications for systemic therapy). The NCCN Head and Neck Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel’s most recent recommendations regarding management of HPV-positive oropharynx cancer and ongoing research in this area.
Validation of the American Association for the Surgery of Trauma Emergency General Surgery Grading System for Colorectal Resection: An EAST Multicenter Study
Aicher, Brittany O. , Betancourt, Alejandro Mohar , Grossman, Michael D., Heise, Holly, Zielinski, Martin D. , Kongkaewpaisan, Napaporn , Kaafarani, Haytham M.A. , Wagner, Afton, Grabo, Daniel, Peck, Gregory , Chang, Gloria, Cullinane, Laura M., Stocker, Benjamin , Simonoski, Ursula J., Catalano, Richard D., Vasileiou, Georgia , Agrawal, Vaidehi , Truitt, Michael S., Pickett, Maryanne L. , Dultz, Linda A. , Müller, Alison, Ong, Adrian W. , Roman, Janika L. San, Barth, Nadine, Fackelmayer, Oliver J. , Velopulos, Catherine G. , Hendrix, Cheralyn J. , Estroff, Jordan M. , Gambhir, Sahil , Jeyamurugan, Kokila , Bugaev, Nikolay , O’Meara, Lindsay , Kufera, Joseph A., Diaz, José J. , Bruns, Brandon , Schroeppel, Thomas J. , Hernandez, Matthew C. , Scott, Michael, Matsushima, Kazuhide , Cullinane, Daniel C. , Posluszny, Joseph A. , Yeh, D. Dante , Nahmias, Jeffry T.

Mayo Clinic

The American Surgeon™ | March 11, 2022 | Volume: 88 | Issue: 5 | Pages: 953-958

10.1177/0003134820960022 | PMID 35275764 Get It

Background The American Association for the Surgery of Trauma (AAST) has developed a grading system for emergency general surgery (EGS) conditions. We sought to validate the AAST EGS grades for patients undergoing urgent/emergent colorectal resection. Methods Patients enrolled in the “Eastern Association for the Surgery of Trauma Multicenter Colorectal Resection in EGS—to anastomose or not to anastomose” study undergoing urgent/emergent surgery for obstruction, ischemia, or diverticulitis were included. Baseline demographics, comorbidity severity as defined by Charlson comorbidity index (CCI), procedure type, and AAST grade were prospectively collected. Outcomes included length of stay (LOS) in-hospital mortality, and surgical complications (superficial/deep/organ-space surgical site infection, anastomotic leak, stoma complication, fascial dehiscence, and need for further intervention). Multivariable logistic regression models were used to describe outcomes and risk factors for surgical complication or mortality. Results There were 367 patients, with a mean (± SD) age of 62 ± 15 years. 39% were women. The median interquartile range (IQR) CCI was 4 (2-6). Overall, the pathologies encompassed the following AAST EGS grades: I (17, 5%), II (54, 15%), III (115, 31%), IV (95, 26%), and V (86, 23%). Management included laparoscopic (24, 7%), open (319, 87%), and laparoscopy converted to laparotomy (24, 6%). Higher AAST grade was associated with laparotomy ( P = .01). The median LOS was 13 days (8-22). At least 1 surgical complication occurred in 33% of patients and the mortality rate was 14%. Development of at least 1 surgical complication, need for unplanned intervention, mortality, and increased LOS were associated with increasing AAST severity grade. On multivariable analysis, factors predictive of in-hospital mortality included AAST organ grade, CCI, and preoperative vasopressor use (odds ratio (OR) 1.9, 1.6, 3.1, respectively). The American Association for the Surgery of Trauma emergency general surgery grade was also associated with the development of at least 1 surgical complication (OR 2.5), while CCI, preoperative vasopressor use, respiratory failure, and pneumoperitoneum were not. Conclusion The American Association for the Surgery of Trauma emergency general surgery grading systems display construct validity for mortality and surgical complications after urgent/emergent colorectal resection. These results support incorporation of AAST EGS grades for quality benchmarking and surgical outcomes research.
Machine Learning for Opportunistic Screening for Osteoporosis from CT Scans of the Wrist and Forearm
Sebro, Ronnie , Garza‐Ramos, Cynthia De la , De la Garza-Ramos, Cynthia

Mayo Clinic

Diagnostics | March 11, 2022 | Volume: 12 | Issue: 3 | Pages: 691

10.3390/diagnostics12030691 | PMID 35328244 Get It

Background: We investigated whether opportunistic screening for osteoporosis can be done from computed tomography (CT) scans of the wrist/forearm using machine learning. Methods: A retrospective study of 196 patients aged 50 years or greater who underwent CT scans of the wrist/forearm and dual-energy X-ray absorptiometry (DEXA) scans within 12 months of each other was performed. Volumetric segmentation of the forearm, carpal, and metacarpal bones was performed to obtain the mean CT attenuation of each bone. The correlations of the CT attenuations of each of the wrist/forearm bones and their correlations to the DEXA measurements were calculated. The study was divided into training/validation (n = 96) and test (n = 100) datasets. The performance of multivariable support vector machines (SVMs) was evaluated in the test dataset and compared to the CT attenuation of the distal third of the radial shaft (radius 33%). Results: There were positive correlations between each of the CT attenuations of the wrist/forearm bones, and with DEXA measurements. A threshold hamate CT attenuation of 170.2 Hounsfield units had a sensitivity of 69.2% and a specificity of 77.1% for identifying patients with osteoporosis. The radial-basis-function (RBF) kernel SVM (AUC = 0.818) was the best for predicting osteoporosis with a higher AUC than other models and better than the radius 33% (AUC = 0.576) (p = 0.020). Conclusions: Opportunistic screening for osteoporosis could be performed using CT scans of the wrist/forearm. Multivariable machine learning techniques, such as SVM with RBF kernels, that use data from multiple bones were more accurate than using the CT attenuation of a single bone.
A novel upper tract ureteroscopic biopsy technique: the “form tackle”
Klett, Dane , Alom, Manaf, Wymer, Kevin , Potretzke, Aaron M. , Potretzke, Aaron, Klett, Dane E

Mayo Clinic

International braz j urol | March 11, 2022 | Volume: 48 | Issue: 2 | Pages: 367-368

10.1590/s1677-5538.ibju.2021.0499 | PMID 34907769 Get It

Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH -wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON T
Tesileanu, C. Mircea S. , Wick, Wolfgang , Clément, Paul M. , Erridge, Sara , Vogelbaum, Michael A. , Nowak, Anna K. , Baurain, Jean‐François , Mason, Warren , Wheeler, Helen , Gill, Sanjeev , Griffin, Matthew, Rogers, Leland , Taal, Walter , Weller, Michael , McBain, Catherine , Linde, Myra E. van , Aldape, Kenneth , Jenkins, Robert B., Hoogstrate, Youri , Heer, Iris de , Atmodimedjo, Peggy N., Dubbink, Hendrikus J. , IJcken, Wilfred F. J. van , Cheung, Kin Jip, Golfinopoulos, Vassilis, Baumert, Brigitta G. , Gorlia, Thierry, French, Pim J. , Bent, Martin J. van den , Sanson, Marc , Wick, Wolfgang , Clement, Paul M , Nowak, Anna K , Baurain, Jean-Francois , Wheeler, Helen , Chinot, Olivier L , Taal, Walter , Weller, Michael , Aldape, Kenneth , Kros, Johan M. , Wesseling, Pieter , von Deimling, Andreas , Hoogstrate, Youri , Dubbink, Hendrikus J , van IJcken, Wilfred F J , Golfinopoulos, Vassilis , French, Pim J , van den Bent, Martin J , Sanson, Marc , Brandes, Alba Ariela , Chinot, Olivier , Rudà, Roberta , Wesseling, Pieter , Deimling, Andreas von , Brouwer, Rutger W. W.

Mayo Clinic

Clinical Cancer Research | March 11, 2022 | Volume: 28 | Issue: 12 | Pages: 2527-2535

10.1158/1078-0432.ccr-21-4283 | PMID 35275197 Get It

Abstract Purpose: In a post hoc analysis of the CATNON trial (NCT00626990), we explored whether adding temozolomide to radiotherapy improves outcome in patients with IDH1/2 wildtype (wt) anaplastic astrocytomas with molecular features of glioblastoma [redesignated as glioblastoma, isocitrate dehydrogenase–wildtype (IDH-wt) in the 2021 World Health Organization (WHO) classification of central nervous system tumors]. Patients and Methods: From the randomized phase III CATNON study examining the addition of adjuvant and concurrent temozolomide to radiotherapy in anaplastic astrocytomas, we selected a subgroup of IDH1/2wt and H3F3Awt tumors with presence of TERT promoter mutations and/or EGFR amplifications and/or combined gain of chromosome 7 and loss of chromosome 10. Molecular abnormalities including MGMT promoter methylation status were determined by next-generation sequencing, DNA methylation profiling, and SNaPshot analysis. Results: Of the 751 patients entered in the CATNON study, 670 had fully molecularly characterized tumors. A total of 159 of these tumors met the WHO 2021 molecular criteria for glioblastoma, IDH-wt. Of these patients, 47 received radiotherapy only and 112 received a combination of radiotherapy and temozolomide. There was no added effect of temozolomide on either overall survival [HR, 1.19; 95% confidence interval (CI), 0.82–1.71] or progression-free survival (HR, 0.87; 95% CI, 0.61–1.24). MGMT promoter methylation was prognostic for overall survival, but was not predictive for outcome to temozolomide treatment either with respect to overall survival or progression-free survival. Conclusions: In this cohort of patients with glioblastoma, IDH-wt temozolomide treatment did not add benefit beyond that observed from radiotherapy, regardless of MGMT promoter status. These findings require a new well-powered prospective clinical study to explore the efficacy of temozolomide treatment in this patient population.
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Ansell, Stephen M. , Barnes, Jeffrey A. , Brammer, Jonathan E. , Clemens, Mark W. , Ghione, Paola , Goodman, Aaron M. , Guitart, Joan , Haverkos, Bradley M. , Hoppe, Richard T. , Jacobsen, Eric D. , Jagadeesh, Deepa , Jones, Allison , Mehta–Shah, Neha , Olsen, Elise A. , Rajguru, Saurabh, Rozati, Sima , Said, Jonathan , Shaver, Aaron C., Shea, Lauren , Sokol, Lubomir , Wu, Peggy A. , Zain, Jasmine , Dwyer, Mary A., Sundar, Hema, Hoppe, Richard T , Ghione, Paola , Horwitz, Steven M. , Ai, Weiyun Z. , Barta, Stefan K , Doǧan, Ahmet , Foss, Francine M. , Halwani, Ahmad , Kallam, Avyakta , Kim, Youn H , Kumar, Kiran Achut , Shinohara, Michi M. , Sokol, Lubomir , Torres‐Cabala, Carlos A. , Wilcox, Ryan A.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 11, 2022 | Volume: 20 | Issue: 3 | Pages: 285-308

10.6004/jnccn.2022.0015 | PMID 35276674 Get It

Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders arising from mature T cells, accounting for about 10% of non-Hodgkin lymphomas. PTCL-not otherwise specified is the most common subtype, followed by angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma, anaplastic lymphoma kinase–positive, anaplastic large cell lymphoma, anaplastic lymphoma kinase–negative, and enteropathy-associated T-cell lymphoma. This discussion section focuses on the diagnosis and treatment of PTCLs as outlined in the NCCN Guidelines for T-Cell Lymphomas.
The utility of P53 immunohistochemistry in the diagnosis of Barrett's oesophagus with indefinite for dysplasia
Januszewicz, Władysław , Pilonis, Nastazja , Sawas, Tarek , Phillips, Richard , O’Donovan, Maria , Miremadi, Ahmad, Malhotra, Shalini , Tripathi, Monika, Blasko, Adrienn, Katzka, David A. , Pietro, Massimiliano di , Fitzgerald, Rebecca C.

Mayo Clinic

Histopathology | March 11, 2022 | Volume: 80 | Issue: 7 | Pages: 1081-1090

10.1111/his.14642 | PMID 35274753 Get It

AimsBarrett's oesophagus with indefinite for dysplasia (BE‐IND) is a subjective diagnosis with a low interobserver agreement (IOA) among pathologists and uncertain clinical implications. This study aimed to assess the utility of p53 immunohistochemistry (p53‐IHC) in assessing BE‐IND specimens.Methods and resultsArchive endoscopic biopsies with a BE‐IND diagnosis from two academic centres were analysed. First, haematoxylin and eosin‐stained slides (H&E) were reviewed by four expert gastrointestinal (GI) pathologists allocated into two groups (A and B). After a washout period of at least 8 weeks, H&E slides were reassessed side‐to‐side with p53‐IHC available. We compared the rate of changed diagnosis and the IOA for all BE grades before and after p53‐IHC. We included 216 BE‐IND specimens from 185 patients, 44.0 and 32.9% of which were confirmed after H&E slide revision by groups A and B, respectively. More than half the cases were reclassified to a non‐dysplastic BE (NDBE), while 5.6% of cases in group A and 7.4% in group B were reclassified to definite dysplasia. The IOA for NDBE, BE‐IND, low‐grade dysplasia (LGD) and high‐grade dysplasia (HGD)/intramucosal cancer (IMC) was 0.31, 0.21, −0.03 and −0.02, respectively. Use of p53‐IHC led to a >40% reduction in BE‐IND diagnoses (P < 0.001) and increased IOA for all BE grades [κ = 0.46 (NDBE), 0.26 (BE‐IND), 0.49 (LGD), 0.35 (HGD/IMC)]. An aberrant p53‐IHC pattern significantly increased the likelihood of reclassifying BE‐IND to definite dysplasia (odds ratio = 44.3, 95% confidence interval = 18.8–113.0).ConclusionP53‐IHC reduces the rate of BE‐IND diagnoses and improves the IOA among pathologists when reporting BE with equivocal epithelial changes.
Sex differences in growth in body mass and psychosocial abilities in children in Head Start
Miccoli, Antonela , Smith, Latasha M. , Hansen, Carina , Lynch, Brian , Toussaint, Loren

Mayo Clinic

Early Child Development and Care | March 11, 2022 | Volume: 192 | Issue: 16 | Pages: 2646-2655

10.1080/03004430.2022.2044322 Get It

American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment
Shonka, David C. , Geiger, J.L. , Park, Jong Chul , Jasim, Sina , Ahmed, Amr H. Abdelhamid , Bible, Keith C. , Brose, Marcia S. , Dabekaussen, Kirsten F. A. A. , Dias‐Santagata, Dora , Ghossein, Ronald , Gopal, Raj K., Ryder, Mabel , Sherman, Eric J. , Shin, Jennifer J. , Stack, Brendan C. , Tuttle, R. Michael , Wirth, Lori J. , Zafereo, Mark , Park, Jong C , Abdelhamid Ahmed, Amr H , Cabanillas, Maria E , Davies, Louise , Ryder, Mabel M, Ryder, Mabel , Ho, Alan L. , Chintakuntlawar, Ashish V. , Seetharamu, Nagashree , Cabanillas, Maria E. , Fagin, James A. , Faquin, William C , Miyauchi, Akira , Nikiforov, Yuri E. , Ringel, Matthew D. , Robinson, Bruce , Sadow, Peter M. , Randolph, Gregory William

Mayo Clinic

Head & Neck | March 11, 2022 | Volume: 44 | Issue: 6 | Pages: 1277-1300

10.1002/hed.27025 | PMID 35274388 Get It

AbstractBackgroundThe development of systemic treatment options leveraging the molecular landscape of advanced thyroid cancer is a burgeoning field. This is a multidisciplinary evidence‐based statement on the definition of advanced thyroid cancer and its targeted systemic treatment.MethodsAn expert panel was assembled, a literature review was conducted, and best practice statements were developed. The modified Delphi method was applied to assess the degree of consensus for the statements developed by the author panel.ResultsA review of the current understanding of thyroid oncogenesis at a molecular level is presented and characteristics of advanced thyroid cancer are defined. Twenty statements in topics including the multidisciplinary management, molecular evaluation, and targeted systemic treatment of advanced thyroid cancer are provided.ConclusionsWith the growth in targeted treatment options for thyroid cancer, a consensus definition of advanced disease and statements regarding the utility of molecular testing and available targeted systemic therapy is warranted.
Ultrasound Guided Biopsy in Patients With HPV‐Associated Oropharyngeal Squamous Cell Carcinoma
Haller, Travis J. , Abel, Kathryn M. Van , Lohse, Christine M. , Douse, Dontre’ M. , Badaoui, Joseph N. , Kasperbauer, Jan L. , Moore, Eric J. , Van Abel, Kathryn M , Yin, Linda X , Douse, Dontre', Kasperbauer, Jan , Moore, Eric J , Yin, Linda X. , Price, Daniel L.

Mayo Clinic

The Laryngoscope | March 11, 2022 | Volume: 132 | Issue: 12 | Pages: 2396-2402

10.1002/lary.30105 | PMID 35275423 Get It

Objectives To identify the differences in sensitivity and accuracy between ultrasound‐guided and palpation‐guided fine needle aspirations (FNA) of suspicious lymph nodes in patients with human papillomavirus (HPV) (+) oropharyngeal squamous cell carcinoma (OPSCC). Additional objectives included identifying patient specific factors affecting biopsy accuracy and evaluating potential differences in accuracy between fine and core needle biopsies. Study Design Retrospective chart review. Materials and Methods A retrospective study of diagnostic sensitivity was completed at a single tertiary care center between 1/1/2006–12/31/2016. Participants included patients who underwent pretreatment FNA biopsy with HPV(+)OPSCC confirmed pathologically following neck dissection or excisional lymph node biopsy. A true positive (TP) on FNA biopsy was defined as an FNA biopsy concerning for squamous cell carcinoma (SCC) that was confirmed on excisional biopsy or neck dissection. A false negative (FN) was defined as a negative FNA but metastatic disease identified on excisional biopsy or neck dissection. Sensitivity was calculated as TPs/(TPs + FNs). Sensitivity was compared among techniques using chi‐square and Fisher exact tests. Results A total of 209 FNA biopsies among 198 patients were included in the study, including 31 (15%) palpation‐guided FNAs, 160 (77%) ultrasound‐guided FNAs, and 18 (9%) ultrasound‐guided FNA + core biopsies. Sensitivity was significantly different among palpation‐guided FNA, ultrasound‐guided FNA, and ultrasound‐guided FNA + core biopsies (48% vs. 83% vs. 94%, respectively; P < .001) but there was no significant difference in sensitivity between ultrasound‐guided FNA versus ultrasound‐guided FNA + core biopsies ( P = .31). Conclusion The use of ultrasound guidance in FNA biopsies of nodal metastases in HPV(+)OPSCC improves sensitivity compared to palpation guidance alone. Ultrasound guided biopsies are preferred in patients with suspected nodal metastasis from HPV(+)OPSCC. Level of Evidence 3 Laryngoscope , 132:2396–2402, 2022